INTRODUCTION
Inhaled glucocorticosteroids are used in asthma therapy for their anti-inflammatory effects (Smith and Bernstein, 1996) . A number of studies have shown that glucocorticosteroids interact with Pgp to either bind to, be transported by, or affect the expression and action of this efflux pump. The high levels and wide tissue distribution of Pgp expression in the adrenal gland, the site of glucocorticosteroid synthesis, provided an early indication that Pgp may play a role in steroid transport (Fojo et al., 1987; Thiebaut et al., 1987) . Consistent with these observations, it was later shown that Pgp transports aldosterone, cortisol and dexamethasone, however the more hydrophobic steroids, β-estradiol, progesterone and testosterone are not substrates for Pgp efflux (Ueda et al., 1992; Ueda et al., 1994) . The incorporation of hydroxyl groups on the steroid ring system at carbons 11, 16, 17 and 21, impart varying degrees of decreased hydrophobicity, and has been shown to determine steroid transport by Pgp (Gruol et al., 1994) . A relationship between increased steroid hydrophobicity and increased retention of the Pgp substrate vinblastine has also been demonstrated (Yang et al., 1989) . In similar studies, Naito et al. (1989) reported inhibition of binding of another Pgp substrate, vincristine, by several steroid hormones including β-estradiol, cortisone, corticosterone, testosterone and progesterone. Finally, steroids have also been shown to regulate Pgp expression. Estrogen and progesterone have been reported to induce murine mdr1 and Pgp expression in the uterus during pregnancy (Arceci et al., 1990) . On the other hand, dexamethasone modulation of Pgp expression appears to be tissue specific (Sérée et al., 1998; Demeule et al., 1999) .
In contrast, there are few reports in the literature on the interactions of β-ligands with Pgp. The cardioselective β-blockers acebutolol, celiprolol and talinolol, have been shown to exhibit Pgp-mediated secretion in intestinal Caco-2 cells (Karlsson et al., 1993; Terao et al., 1996; Hilgendorf et al., 2000) . Propranolol uptake was reported to be increased by several Pgp ligands including cyclosporin A, progesterone and Rh123, in conjuctival epithelium (Yang et al., 2000) . More recently, Pgp was shown to restrict the transport of bunitrolol across the blood-brain barrier (Matsuzaki et al., 1999) . Inhaled β 2 -adrenergic agonists such as albuterol and terbutaline provide quick bronchodilatory relief in asthma patients (Smith and Bernstein, 1996) . There are no reports, however, on the involvement of Pgp in the pulmonary absorption of anti-asthmatic agents.
The lung is known to express low levels of Pgp relative to other tissues (Fojo et al., 1987) . In particular, Pgp expression has been demonstrated in normal human bronchial epithelium and expression levels in normal lung have been reported to exceed those in cancerous tissue (Pavelic et al., 1993; Abe et al., 1994) . Although the exact role of Pgp in the lung is unknown, Pgp may function to protect the lung from toxic levels of xenobiotics, as has been proposed for other tissues (Thiebaut et al., 1987) . We have recently demonstrated functional Pgp activity in Calu-3 cells, a model of the human sub-bronchial epithelium (Hamilton et al., 2001a) . If Pgp does indeed play a role in restricting the absorption of potential substrates in the lung, then circumvention of this pathway may improve the delivery of pulmonary therapeutics. With this is mind, we sought to investigate if Pgp activity in Calu-3 cells could be inhibited with a number of steroids and β-ligands varying in chemical structure, lipophilicity and their Modulation of P-glycoprotein activity in Calu-3 cells using steroids and bligands. Int. J. Pharm. 228, 171-179. PMID: 11576779. Publisher's official version: <http://dx.doi.org/10.1016/S0378-5173(01)00836-5> . Open Access version: http://kuscholarworks.ku.edu/dspace/. 4 intrinsic ability to be transported by Pgp (Figures 1, 2, 3 ). Although Rh123 has been shown to be a substrate for both Pgp and MRP1 (Twentyman et al., 1994; Versantvoort et al., 1996) , we have shown predominant Pgp activity in Calu-3 cells (Hamilton et al., 2001b ) using this marker compound.
MATERIALS AND METHODS

Materials
Calu-3 cells were obtained from the American Type Culture Collection (Rockville, MD). Cell culture medium and buffer solutions were obtained from Gibco BRL (Gaithersburg, MD). Accumulation studies were all performed in pH 7.4 standard phosphate buffered saline (PBS) 
Cell culture
All cell lines were maintained in a 95% humidified/10%CO 2 atmosphere at 37°C. Calu-3 cells were used between passages 19 and 40. The cells were grown in 150 cm 2 flasks and maintained in a 1:1 mixture of
Ham's F12:DMEM containing 10% fetal bovine serum (FBS), 100 µg/ml penicillin G and 100 µg/ml streptomycin sulfate. When the cells reached 90% confluency (approximately 4-5 days) they were subcultured at a 1:2 split ratio using 0.25% trypsin/0.1% EDTA. Caco-2 cells were cultured in DMEM containing 10% FBS, 1% non-essential amino acids, 2 mM glutamine, 100 µg/ml penicillin G and 100 µg/ml streptomycin sulfate. A549 cells were maintained in Ham's F-12 medium supplemented with 10% FBS, 100 µg/ml penicillin G and 100 µg/ml streptomycin sulfate.
Rh123 accumulation assay
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Cells were seeded onto 12 well cluster dishes at a density of 5 x 10 5 cells/cm 2 (1 ml per well).
The culture medium was changed every other day after seeding until a confluent monolayer was formed (by day 4) as determined by light microscopy. Experiments were performed in PBSA. All experiments were performed with gentle agitation (~ 30 rpm) at 37°C. The growth medium was first aspirated off and then the cells were rinsed three times with pre-warmed (37°C) PBSA. The monolayers were then equilibrated either in 1 ml PBSA for 1 hour at 37°C for control experiments or equilibrated for 30 minutes in PBSA alone, followed by another 30 minute pre-incubation with the steroid, β-ligand or excipient. CsA (5 µM) was used as the positive control. Rh123 accumulation was then performed for 2 hours with or without modulator present. At the end of the experiment, the drug solution was removed by aspiration and the monolayers were immediately rinsed three times with ice-cold PBSA. Each monolayer was solubilized for 30 minutes (37°C) with 1 ml of lysing solution (0.5% v/v Triton X-100 in 0.2 N NaOH). For cells grown in 96 well format (0.32 cm 2 total surface area), the following adjustments were made to the protocol outlined above. Cells were plated at the same density with 100 µl per well, and a confluent monolayer was formed by day 2. Volumes for preincubations and incubations were 100 µl and cells were lysed in 200 µl volume. For both plating conditions, cell lysates were assayed using a microplate fluorescence reader (Bio-Tek Instruments, Winooski, VT) at excitation/emission wavelengths of 485 nm/520 nm, then quantified against standard curves of Rh123 in lysing solution. The fluorescence of the cell lysates was corrected for autofluorescence of untreated cells. The protein content of each monolayer was then determined using the BCA protein assay reagent kit. Results were 
Software analysis
All experiments were performed at least in quadruplicate. Data are presented as mean ± standard deviation. Statistical significance and linear regression analyses were performed using the unpaired student's t-test (Sigma Plot version 4.01) determined at the 95% confidence level. Estimated log P values (log Kow) were retrieved from the online-interactive Syracuse Research Corporation KowWin program (http://esc.syrres.com/interkow/kowdemo.htm).
RESULTS
Effect of progesterone, dexamethasone and their analogs
For most agents tested, an increase in Rh123 accumulation was not observed until 100 µM concentration. Figure 4 shows the correlation between estimated log P (log Kow) and % Rh123 of control values. Log Kow values were plotted rather than log P values due to incomplete availability of measured log P values in the literature. It should be noted that the overall data trend was not affected by plotting log Kow rather than log P. Modulation efficiency appears to fall into three distinct categories, relative to log Kow; log Kow of 3.67, log Kow between 3.08 and 3.27 and log Kow less than 2.18. No modulation was observed with steroids that are highly transported by Pgp (aldosterone, dexamethasone, 11β, 17α, 21-OH progesterone). On the other hand, testosterone and progesterone, compounds that do not display Pgp transporting activity, increased Rh123 accumulation approximately 1.7 and 4.0 fold, respectively. Progesterone analogs with varying degrees of hydroxyl substitution showed varying degrees of modulation. The inhalation steroids also varied in their Pgp inhibitory effects, with triamcinolone being the least effective of this series. A summary of all the steroids tested along with their corresponding log P and log Kow values relative to modulation efficiency is shown in Table 1 .
Effect of β-ligands
A concentration dependent effect was also observed (1 µM to 1 mM) for all the compounds tested, with higher concentrations showing greater inhibitory effects on Rh123 efflux. Representative doseresponse curves are shown in Figure 5 for the β-ligands nadolol and metoprolol. Figure 6 shows the correlation between log P and Rh123 accumulation (as % control) for the seven β-ligands tested (100 µM). The data for the 100 µM treatment are summarized in Table 2 using a ranking system similar to that provided for the steroids in Table 1 . A clear trend was observed between increasing log P and the ability to inhibit Rh123 efflux. However, the Pgp substrate propranolol gave the largest increase in Rh123 accumulation. Cellular toxicity was observed with this agent at > 100 µM, which was manifested as a decrease in Rh123 and detachment of the cell monolayer from the plastic support during the incubation period. Metoprolol, acebutolol and timolol showed similar inhibitory effects relative to each other. No modulation was observed with those compounds exhibiting log P values < 1. No effect on Rh123 accumulation was observed with the bronchodilator, albuterol.
Effect of ethanol, glycerol and palmitoyl carnitine
The effects of various formulation additives on Pgp activity were investigated (data not shown). No effect on Rh123 accumulation was observed with 0.1% (v/v) and 1.0% (v/v) glycerol. Similarly, 0.05% (v/v) and 0.5% (v/v) DMSO; 0.08% EtOH; 0.08% (v/v) and 0.82% MeOH solvent controls did not affect Rh123 accumulation. The permeation enhancer palmitoyl carnitine did not affect Rh123 accumulation at 10 µM. The 100 µM treatment, however, also resulted in cellular toxicity similar to those observed with high concentrations of propranolol.
DISCUSSION
We show here that steroids and β-ligands vary in their ability to modulate Pgp in Calu-3 cells.
Whereas both therapeutic classes inhibit Rh123 efflux with increasing hydrophobicity, steroidal
Pgp substrates are non-modulating while the β-ligand substrate, propranolol was the most effective inhibitor in its class. Although propranolol and progesterone exhibit similar log P values (3.21 and 3.26, respectively), progesterone increased Rh123 accumulation 4-fold, while propranolol produced a 2-fold increase in accumulation. Thus, progesterone appears to be a more potent inhibitor of Pgp efflux at equimolar concentrations using the model substrate, Rh123.
Certain structural elements have previously been identified as essential for recognition by Pgp.
These include a basic nitrogen atom, and the presence of at least one planar aromatic ring (Pearce et al., 1989) . The β-ligands tested are all weak bases, and therefore positively charged at physiological pH (pKa ≈ 9.5). This additional feature would make these compounds ideal (Seelig, 1998) . Furthermore, it has been shown that carbonyl groups and ether linkages are prevalent in Pgp substrates (Seelig, 1998) . Propranolol possesses an ether linkage coupled to a fused aromatic ring system. This unique structural combination is absent in any of the other β-ligands tested, and may account for the enhanced inhibitory effect of this compound.
On the other hand, the steroids tested represent un-ionizable compounds, and lack a basic nitrogen atom, in addition to aromaticity. Their ability to be recognized by Pgp therefore may be a function of relative hydrophobicity, rather than the structural requirements outlined above (Ueda et al., 1997) . The ability of these steroids to modulate Pgp also appears to follow the same pattern observed for substrate recognition. The highly transported Pgp substrates aldosterone, dexamethasone and the tri-hydroxyl substituted progesterone analog, did not modulate Rh123 efflux. The moderately transported progesterone analogs (mono-and dihydroxyl substituted) gave intermediate effects, increasing Rh123 accumulation 1.4 to 2.1 fold.
Interestingly, the non-transported steroid progesterone was a greater inhibitor of Rh123 efflux than CsA (% Rh123 control = 307.1 ± 18.4, 5 µM CsA; 405.0 ± 38.5, 100 µM progesterone).
Testosterone differs from progesterone by possessing a hydroxyl group on the position-20 carbon, however, this steroid did affect Pgp activity (1.7-fold). Thus, hydroxylation at carbon 20 may be important for steroidal modulation of this efflux pump transporter.
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Of the inhalation steroids tested, budenoside was the most potent modulator, second only to CsA in Pgp inhibitory effect. The closely related steroid, flunisolide, displayed intermediate effects on Pgp activity. These differences can most likely be attributed to chemical structure (Figure 2 ). The only other fluorinated steroid tested was triamcinolone, for which no modulation of Pgp activity was observed despite possessing two hydroxyl groups on carbons 16
and 17.
Finally, we investigated the ability of various formulation additives to affect Pgp activity. here at the given concentrations as vehicle controls; none of these agents caused an apparent effect on Pgp activity. The permeation enhancer, palmitoyl carnitine did, however, prove to be cytotoxic at 100 µM. This result is consistent with previous studies reporting tissue irritancy of this formulation agent.
CONCLUSIONS
We have shown that steroids and β-ligands can be used to modulate Pgp activity in vitro, however, both classes of agents display unique physico-chemical and structural features that may explain the differences observed in modulation efficiency. It should be noted, however, that a more detailed structure activity relationship would be needed to confirm the data and Modulation of P-glycoprotein activity in Calu-3 cells using steroids and bligands. Int. J. Pharm. 228, 171-179. PMID: 11576779. Publisher's official version: <http://dx.doi.org/10.1016/S0378-5173(01)00836-5> . Open Access version: http://kuscholarworks.ku.edu/dspace/.
10 hypotheses presented here. Of the 100 compounds initially detailed by Seelig et al. (1998) for Pgp substrate activity, the only bronchodilator listed was epinephrine, which was reported not to be a substrate for the efflux pump transporter. It may well be that due to the low levels of Pgp found within the lung, the necessity for circumvention of this transporter is unwarranted.
The physiological relevance of the relatively high concentrations of compound needed to produce an inhibition of Pgp-mediated efflux needs to be explored further. Table 1 . A log P or log Kow value for flunisolide (rank #7) could not be obtained. Table 2 . Taylor 
